权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Leveraging glucose transport and the adaptive fasting response to modulate hepatic metabolism

利用葡萄糖转运和适应性禁食反应来调节肝脏代谢

基本信息

批准号：
10295349
负责人：
Brian Jesse DeBosch
金额：
$ 44.82万
依托单位：
WASHINGTON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-08-25 至 2025-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10295349
关键词：
Abate Acute Attenuated Autophagocytosis Biochemical Calories Carbohydrates Cardiovascular system Cell membrane Cessation of life Data Deoxyglucose Development Diabetes Mellitus Diet Disaccharides Disease Exhibits Extrahepatic FGF21 gene Fasting Fatty Liver Fatty acid glycerol esters Gene Deletion Genetic Glucose Glucose Transporter Goals Hepatic Hepatocyte Homeostasis Imaging Techniques In Vitro Individual Insulin Insulin Resistance Intravenous Kidney Kinetics Knock-out Lead Ligands Liposomes Liver Liver diseases Location Lysosomes Mass Spectrum Analysis Measures Mediating Metabolic Metabolic Diseases Metabolic Pathway Metabolic syndrome Metabolism Microscopic Modality Mus Mutant Strains Mice Non-Insulin-Dependent Diabetes Mellitus Oral Overnutrition Pathway interactions Peripheral Pharmaceutical Preparations Pharmacology Phenotype Prediabetes syndrome Radiolabeled Regulation Resistance Retina Role SLC2A1 gene Signal Transduction Steatohepatitis Substrate Specificity Testing Therapeutic Effect Thermogenesis Time Trehalase Trehalose Whole Organism adenylate kinase base cardiovascular risk factor chronic liver disease defined contribution dietary established cell line fasting glucose glucose transport improved in vivo in vivo imaging indexing inhibitor/antagonist knock-down late endosome liver metabolism mimetics mouse model mutant non-alcoholic fatty liver disease novel novel strategies prevent receptor response sugar therapeutic target

项目摘要

Non-alcoholic fatty liver disease (NAFLD) is a common and morbid metabolic disease that independently predicts development of type 2 diabetes mellitus and its cardiovascular, renal and retinal complications. More than one billion individuals have NAFLD, making this the most common chronic liver disease worldwide. A barrier to effectively treating and preventing this disease and its complications is the lack of effective NAFLD treatments. Our long-term goal is to understand the underlying glucose metabolic pathways that lead to NAFLD, so that we can precisely modulate these pathways to treat or prevent its progression. We identified the hepatic carbohydrate carrier, GLUT8, as a therapeutic target because: (i.) GLUT8 promotes diet-induced hepatic steatosis and metabolic syndrome and (ii.) the disaccharide and glucose mimetic trehalose inhibits GLUT8 and activates an adaptive fasting response (e.g. AMP kinase and autophagy), to reverse hepatic steatosis. The objective here is to define the interaction between hepatocyte glucose transport, trehalose, and adaptive hepatocyte fasting responses. Our preliminary data suggest that acute hepatocyte-selective GLUT8 knockdown and hepatocyte- specific germline GLUT8 gene deletion (GLUT8 LKO mice) each induce hepatocyte fasting signals and peripheral thermogenesis. We therefore hypothesize that genetic and pharmacological hepatocyte GLUT8 blockade induces thermogenesis and confers resistance to hepatic steatosis. The two Specific Aims are to 1) Identify mechanisms by which GLUT8 regulates hepatic and extrahepatic metabolism, and 2) Define mechanisms mediating trehalose-induced thermogenesis and protection from NAFLD. We will accomplish these aims by leveraging novel experimental mouse models and unique in vivo imaging techniques. Completing these aims informs how to optimally target hepatocyte glucose transport to augment hepatocyte and whole-organism energy homeostasis.

非酒精性脂肪性肝病(NAFLD)是一种常见的病态代谢性疾病，可独立预测2型糖尿病及其心血管、肾脏和视网膜并发症的发生。超过10亿人患有非酒精性脂肪肝，使其成为全球最常见的慢性肝病。有效治疗和预防这种疾病及其并发症的一个障碍是缺乏有效的NAFLD治疗。我们的长期目标是了解导致NAFLD的潜在葡萄糖代谢途径，以便我们能够准确地调节这些途径以治疗或防止其进展。我们确定肝脏碳水化合物载体GLUT8为治疗靶点，因为：(I)GLUT8促进饮食诱导的肝脏脂肪变性和代谢综合征和(Ii)二糖和葡萄糖类似物海藻糖抑制GLUT8并激活适应性空腹反应(例如AMP激酶和自噬)，以逆转肝脏脂肪变性。这里的目的是确定肝细胞葡萄糖转运、海藻糖和适应性肝细胞禁食反应之间的相互作用。我们的初步数据表明，急性肝细胞选择性GLUT8基因敲除和肝细胞特异性生殖系GLUT8基因缺失(GLUT8 LKO小鼠)均可诱导肝细胞禁食信号和外周产热。因此，我们假设，基因和药物阻断肝细胞GLUT8诱导产热，并对肝脏脂肪变性具有抵抗力。这两个特定的目的是：1)确定GLUT8调节肝脏和肝外代谢的机制；2)确定介导海藻糖诱导的生热和保护NAFLD的机制。我们将通过利用新的实验小鼠模型和独特的体内成像技术来实现这些目标。完成这些目标，提示如何最佳地靶向肝细胞葡萄糖转运，以增强肝细胞和整个机体的能量动态平衡。